As internal comparison, RES-CRC-SCs were exposed to two representative pharmacological agents we previously demonstrated to potently sensitize to ATR/CHK1 inhibitors: triapine and adavosertib, which inhibit, respectively, the ribonucleotide reductase regulatory subunit M2 (RRM2) and WEE1 G2 checkpoint kinase (WEE1). Here, CHEK1 is linked to colorectal carcinoma.